Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma

BACKGROUND: Combined treatment with BRAFi and/or MEK inhibitors (MEKi) improves outcomes in advanced melanoma patients in comparison with monotherapy. OBJECTIVE: We aim to report real-world treatment efficacy and safety of vemurafenib (V) and vemurafenib + cobimetinib (V + C) from 10 years of practi...

Descripción completa

Detalles Bibliográficos
Autores principales: Piejko, Karolina, Cybulska-Stopa, Bożena, Ziętek, Marcin, Dziura, Robert, Galus, Łukasz, Kempa-Kamińska, Natasza, Ziółkowska, Barbara, Rutkowska, Ewa, Kopciński, Tomasz, Kubiatowski, Tomasz, Bal, Wiesław, Suwiński, Rafał, Mackiewicz, Jacek, Kamińska-Winciorek, Grażyna, Czarnecka, Anna M., Rutkowski, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042754/
https://www.ncbi.nlm.nih.gov/pubmed/36906728
http://dx.doi.org/10.1007/s11523-023-00954-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042754/
https://www.ncbi.nlm.nih.gov/pubmed/36906728
http://dx.doi.org/10.1007/s11523-023-00954-w

Ejemplares similares